

PRESS RELEASE


UPPSALA, SWEDEN
December 8, 2009

Senzime's new biosensor instrument shows excellent results for measuring glucose in bioreactors

- Milestone results achieved in critical beta-tests.

During Q3-4 2009, several tests have been performed at different sites where bioreactors are used for cell cultures, both in Sweden and in the Netherlands. During the tests glucose concentration was measured during more than 360 hours and Senzime was able to verify the accuracy of measurements against standard reference methods. The results show that Senzime's instrument, including the company's patented biosensor technology, works very well.

Being performed on sites of both Dutch and Swedish large pharmaceutical companies, the test runs monitored cell cultures every ten minutes for more than 360 hours. External glucose was added several times to check the sensor's ability to response to instant increases in glucose level. Results from the tests are exemplified by graphs like the one below, proving the instrument's strong performance.





“Not only does the instrument meet the updated specification that was defined in June 2009, it has even exceeded it. For example, the number of measurements with the same sensor are about twice as many compared to target”, says Staffan Boström, CEO at Senzime. “Successful measurements at end customer sites like these are very important steps towards a market launch of our instrument. We are approaching that important goal for Senzime”, Staffan Boström concludes.

The Bioreactor Market

Pharmaceuticals production is done all over the world with a set of basic technologies. Biotechnology is representing an increasingly larger share of the market, compared to traditional pharma production methods.

In fermentation, which is one way that biotechnology is used for producing pharmaceuticals, cell cultures are placed in bioreactors under favourable conditions so that they can produce key substances for different pharma compounds. In order to achieve maximum output from these cell cultures, there is demand for constant optimization of the conditions in the reactor. Therefore, the bioreactor processes must be continuously monitored and analyzed. One of the most important analytes is glucose, which is the nutrient the cell cultures use to survive and become productive.

In today’s production, samples are drawn manually from the bioreactors. These samples are then transferred to containers, each analyzed separately one by one. The manual set-up of the operation involves significant workload on staff and a high risk for sample contamination. In real life this means that samples are drawn more seldom than what is preferred, yielding a lower than optimum output of the fermentation process.

Senzime meets demands from the bioreactor industry, offering an instrument that monitors bioreactors by continuously and automatically drawing and analyzing samples. Customers save on manual labour costs, get more optimal bioreactor conditions and hence higher output from production, and meet higher demands for traceability put forth by e.g. the FDA.

For more information, please visit www.senzime.com or contact:

Staffan Boström, CEO
Tel. +46 (0)18 51 56 40
Mobile +46 (0)70 607 10 02

About Senzime

Uppsala based Senzime, founded in 1999, has developed a biosensor which makes it possible to continuously and automatically monitor critical components in complex biological fluids. The need for such on-line measurements is increasing in a range of industries, for example in pharmaceutical production and health care.

Senzime’s product offering consists of a measurement instrument and disposable sensor units, similar to the machine/filter combination one would find in a modern dialysis machine.

Senzime AB (publ)
Vallvägen 4 A, 756 51 Uppsala, Sweden
Phone +46 (0)18 51 56 40 - Fax +46 (0)18 51 56 30
www.senzime.com



In parallel with working in the pharmaceutical production field (bioreactors/fermentation), Senzime is adapting its instrument for automated and continuous monitoring of whole blood glucose at intensive care units. The first patient was monitored by a Senzime instrument in June 2009.

The company's largest owners are members of the Crafoord family, primarily known for its key role in developing Swedish medical device company Gambro.

Senzime is a publicly listed company and its shares trades at Swedish AktieTorget (www.aktietorget.se).